CA2491572A1 - Abuse-deterrent pharmaceutical compositions of opiods and other drugs - Google Patents

Abuse-deterrent pharmaceutical compositions of opiods and other drugs Download PDF

Info

Publication number
CA2491572A1
CA2491572A1 CA002491572A CA2491572A CA2491572A1 CA 2491572 A1 CA2491572 A1 CA 2491572A1 CA 002491572 A CA002491572 A CA 002491572A CA 2491572 A CA2491572 A CA 2491572A CA 2491572 A1 CA2491572 A1 CA 2491572A1
Authority
CA
Canada
Prior art keywords
drug
composition
abuse
prone
lipophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002491572A
Other languages
French (fr)
Other versions
CA2491572C (en
Inventor
Jane Hirsh
Alexander M. Klibanov
Timothy M. Swager
Stephen L. Buchwald
Whe Yong Lo
Alison B. Fleming
Roman V. Rariy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Collegium Pharmaceutical Inc
Original Assignee
Collegium Pharmaceutical, Inc.
Jane Hirsh
Alexander M. Klibanov
Timothy M. Swager
Stephen L. Buchwald
Whe Yong Lo
Alison B. Fleming
Roman V. Rariy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30119451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2491572(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Collegium Pharmaceutical, Inc., Jane Hirsh, Alexander M. Klibanov, Timothy M. Swager, Stephen L. Buchwald, Whe Yong Lo, Alison B. Fleming, Roman V. Rariy filed Critical Collegium Pharmaceutical, Inc.
Publication of CA2491572A1 publication Critical patent/CA2491572A1/en
Application granted granted Critical
Publication of CA2491572C publication Critical patent/CA2491572C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An abuse-deterrent pharmaceutical composition has been developed to reduce t he likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble, but enzymatically degradable by enzymes present in the human gastrointestinal tract. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the compositio n is broken down or dissolved gradually within the GI tract by a combination o f enzymatic degradation, surfactant action of bile acids, and mechanical erosi on.

Claims (32)

1. An orally administerable abuse-deterrent pharmaceutical composition comprising a therapeutically effective amount of a drug prone to abuse selected from the group of compositions consisting of (a) a composition comprising a therapeutically effective amount of a lipophilic derivative of a drug prone to abuse, and (b) a water-insoluble, preferably lipophilic, formulation comprising a therapeutically effective amount of a drug prone to abuse.
2. The composition of claim 1 comprising a therapeutically effective amount of a lipophilic derivative of a drug prone to abuse in one or more pharmaceutically acceptable excipients.
3. The composition of Claim 1, wherein the composition is a controlled-release pharmaceutical composition.
4. The composition of Claim 1, wherein the composition prevents the immediate release of a substantial portion of incorporated drug when the physical integrity of the composition is compromised and the resulting material is exposed to an aqueous medium.
5. The composition of Claim 4, wherein the portion of the drug released immediately is less than 80% of the total amount of drug incorporated into formulation.
6. The composition of Claim 1, wherein the composition prevents the immediate release of a substantial portion of incorporated drug when the physical integrity of the composition is compromised and the resulting material is exposed to a non-aqueous medium.
7. The composition of Claim 6, wherein the portion of the drug released immediately is less than 80% of the total amount of the drug incorporated into the composition.
8. The composition of Claim 1 wherein the drug prone to abuse is selected from the group consisting of 1-phenylcyclohexylamine, 1-piperidinocyclohexanecarbonitrile, alfentanil, alphacetylmethadol, alphaprodine, alprazolam, amobarbital, amphetamine, anileridine, apomorphine, aprobarbital, barbital, barbituric acid derivative, bemidone, benzoylecgonine, benzphetamine, betacetylmethadol, betaprodine, bezitramide, bromazepam, buprenorphine, butabarbital, butalbital, butorphanol, camazepam, cathine, chloral, chlordiazepoxide, clobazam, clonazepam, clorazepate, clotiazepam, cloxazolam, cocaine, codeine, chlorphentermine, delorazepam, dexfenfluramine, dextromoramide, dextropropoxyphen, dezocine, diazepam, diethylpropion, difenoxin, dihydrocodeine, dihydromorphine, dioxaphentyl butyrate, dipanone, diphenoxylate, diprenorphine, ecgonine, enadoline, eptazocine, estazolam, ethoheptazine, ethyl loflazepate, ethylmorphine, etorphine, femproponex, fencamfamin, fenfluramine, fentanyl, fludiazepam, flunitrazepam, flurazepam, glutethimide, halazepam, haloxazolam, hexalgon, hydrocodone, hydromorphone, isomethadone, hydrocodone, ketamine, ketazolam, ketobemidone, levanone, levoalphacetylmethadol, levomethadone, levomethadyl acetate, levomethorphan, levorphanol, lofentanil, loperamide, loprazolam, lorazepam, lormetazepam, lysergic acid, lysergic acid amide, mazindol, medazepam, mefenorex, meperidine, meptazinol, metazocine, methadone, methamphetamine, methohexital, methotrimeprazine, methyldihydromorphinone, methylphenidate, methylphenobarbital, metopon, morphine, nabilone, nalbuphine, nalbupine, nalorphine, narceine, nefopam, nicomorphine, nimetazepam, nitrazepam, nordiazepam, normethadone, normorphine, oxazepam, oxazolam, oxycodone, oxymorphone, pentazocine, pentobarbital, phenadoxone, phenazocine, phencyclidine, phendimetrazine, phenmetrazine, pheneridine, piminodine, prodilidine, properidine, propoxyphene, racemethorphan, racemorphan, racemoramide, remifentanil, secobarbital, sufentanil, talbutal, thebaine, thiamylal, thiopental, tramadol, trimeperidine, vinbarbital, allobarbitone, alprazolam, amylobarbitone, aprobarbital, barbital, barbitone, benzphetamine, brallobarbital, bromazepam, brotizolam, buspirone, butalbital, butobarbitone, butorphanol, camazepam, captodiame, carbromal, carfentanil, carpipramine, cathine, chloral, chloral betaine, chloral hydrate, chloralose, chlordiazepoxide, chlorhexadol, chlormethiazole edisylate, chlormezanone, cinolazepam, clobazam, potassium clorazepate, clotiazepam, cloxazolam, cyclobarbitone, delorazepam, dexfenfluramine, diazepam, diethylpropion, difebarbamate, difenoxin, enciprazine, estazolam, ethyl loflazepate, etizolam, febarbamate, fencamfamin, fenfluramine, fenproporex, fluanisone, fludiazepam, flunitraam, flunitrazepam, flurazepam, flutoprazepam, gepirone, glutethimide, halazepam, haloxazolam, hexobarbitone, ibomal, ipsapirone, ketazolam, loprazolam mesylate, lorazepam, lormetazepam, mazindol, mebutamate, medazepam, mefenorex, mephobarbital, meprobamate, metaclazepam, methaqualone, methohexital, methylpentynol, methylphenobarbital, midazolam, milazolam, morphine, nimetazepam, nitrazepam, nordiazepam, oxazepam, oxazolam, paraldehyde, pemoline, pentabarbitone, pentazocine, pentobarbital, phencyclidine, Phenobarbital, phendimetrazine, phenmetrazine, phenprobamate, phentermine, phenyacetone, pinazepam, pipradol, prazepam, proxibarbal, quazepam, quinalbaritone, secobarbital, secbutobarbitone, sibutramine, temazepam, tetrazepam, triazolam, triclofos, zalepan, zaleplon, zolazepam, zolpidem, and zopiclone.
9. The composition of Claim 2, wherein the lipophilic derivative of a drug is a free base or a free acid of the drug.
10. The composition of Claim 2, wherein the lipophilic derivative of a drug is a salt comprising the ionized drug and a lipophilic counter-ion.
11. The composition of Claim 2, wherein the lipophilic derivative of a drug is a complex comprising one or more components selected from the group consisting of drug molecules, metal cations, and lipophilic counter-ions.
12. The composition of Claim 2, wherein the lipophilic derivative of a drug is a complex comprising one or more components selected from the group consisting of drug molecules, metal cations, and cyclodextrin molecules.
13. The composition of Claim 2 wherein the drug is complexed with a metal cation selected from the group consisting of zinc, calcium, magnesium, bismuth and combinations thereof.
14. The composition of Claim 11 wherein the drug is oxycodone, and wherein the metal cation is selected from the group consisting of zinc, calcium, magnesium, and bismuth and the lipophilic counter-ion is selected from the group consisting of stearate, oleate, palmitate, laurate and linoleate.
15. The composition of Claim 2, wherein the lipophilic derivative of a drug is a complex comprising the drug and a cyclodextrin.
16. The composition of Claim 2, wherein the lipophilic derivative of a drug is an ester or amide formed between the drug and a fatty acid.
17. The composition of Claim 1, wherein the drug is incorporated into a plurality of individual microparticles comprising a material that is either slowly soluble in water or water insoluble.
18. The composition of Claim 17 wherein the microparticles comprise a wax or wax-like material.
19. The composition of Claim 17 wherein the microparticles comprise a fat or a fatty substance.
20. The composition of Claim 17 wherein the microparticles comprise a material selected from the group consisting of naturally water insoluble proteins, naturally water insoluble polysaccharides, naturally water insoluble lipids and phospholipids, cross-linked water soluble proteins, cross-linked water soluble polysaccharides, cross-linked water soluble cyclodextrins and combinations thereof.
21. The composition of Claim 17 wherein the individual microparticles are coated with one or more independent layers, where at least one of the layers is water insoluble and is degraded by enzymes of the human gastrointestinal tract.
22. The composition of Claim 1 wherein the drug is in the form of individual drug particles coated with one or more independent layers where at least one of the layers is water insoluble and is degraded by enzymes of the human gastrointestinal tract.
23. The composition of Claim 21 wherein at least one of the layers is water-insoluble, organic solvent-insoluble, and degradable by enzymes present in the human gastrointestinal tract.
24. The composition of Claim 21 comprising materials wherein a combination of these materials is not soluble in water, organic solvent, or any combination thereof.
25. The composition of Claim 21 wherein the composition is not completely soluble, and wherein the drug is not fully released in a single solvent or enzyme solution.
26. The composition of Claim 21 wherein the enzymatically degradable layer(s) comprise a material selected from the group consisting of naturally water insoluble proteins, naturally water insoluble polysaccharides, naturally water insoluble lipids and phospholipids, cross-linked proteins, cross-linked polysaccharides, and combinations thereof.
27. The composition of Claim 1 wherein the drug prone to abuse is co-administered with a drug that has no appreciable abuse potential.
28. The composition of claim 1 formulated for the drug to be immediately released upon oral administration.
29. The composition of claim 1 wherein the drug prone to abuse is oxycodone.
30. A method of manufacturing an abuse-resistant pharmaceutical composition comprising homogeneously dispersing a therapeutically effective amount of a drug prone to abuse, in one or more pharmaceutically acceptable carrier(s), diluent(s), and/or additives, to form an orally administerable abuse-deterrent pharmaceutical composition comprising a therapeutically effective amount of a drug prone to abuse selected from the group of compositions consisting of (a) a composition comprising a therapeutically effective amount of a lipophilic derivative of a drug prone to abuse, and (b) a water-insoluble, preferably lipophilic, formulation comprising a therapeutically effective amount of a drug prone to abuse, as defined by any of claims 1-29.
31. The method of claim 30 further comprising formulating the composition into a capsule or tablet.
32. A method of administering an abuse-resistant pharmaceutical composition comprising orally administering to a patient in need thereof an abuse-deterrent pharmaceutical composition comprising a therapeutically effective amount of a drug prone to abuse selected from the group of compositions consisting of (a) a composition comprising a therapeutically effective amount of a lipophilic derivative of a drug prone to abuse, and (b) a water-insoluble, preferably lipophilic, formulation comprising a therapeutically effective amount of a drug prone to abuse, as defined by any of claims 1-29.
CA2491572A 2002-07-05 2003-07-07 Abuse-deterrent pharmaceutical compositions of opiods and other drugs Expired - Fee Related CA2491572C (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US39387602P 2002-07-05 2002-07-05
US60/393,876 2002-07-05
US43652302P 2002-12-23 2002-12-23
US60/436,523 2002-12-23
US44322603P 2003-01-28 2003-01-28
US60/443,226 2003-01-28
US46351803P 2003-04-15 2003-04-15
US46351403P 2003-04-15 2003-04-15
US60/463,518 2003-04-15
US60/463,514 2003-04-15
PCT/US2003/021095 WO2004004693A1 (en) 2002-07-05 2003-07-07 Abuse-deterrent pharmaceutical compositions of opiods and other drugs

Publications (2)

Publication Number Publication Date
CA2491572A1 true CA2491572A1 (en) 2004-01-15
CA2491572C CA2491572C (en) 2010-03-23

Family

ID=30119451

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2491572A Expired - Fee Related CA2491572C (en) 2002-07-05 2003-07-07 Abuse-deterrent pharmaceutical compositions of opiods and other drugs

Country Status (6)

Country Link
US (6) US7399488B2 (en)
EP (1) EP1594467A4 (en)
JP (5) JP4694207B2 (en)
AU (1) AU2003247876B2 (en)
CA (1) CA2491572C (en)
WO (1) WO2004004693A1 (en)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
WO1999032119A1 (en) 1997-12-22 1999-07-01 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
NZ529928A (en) 1999-10-29 2005-10-28 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR101045144B1 (en) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
ATE493130T1 (en) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc MEDICINAL FORM CONTAINING OPIOID AGAINST ABUSE
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP2243471A1 (en) * 2002-04-05 2010-10-27 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
PT1492511E (en) 2002-04-09 2009-04-09 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
JP4694207B2 (en) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド Abuse deterrent pharmaceutical compositions for opioids and other drugs
US10004729B2 (en) * 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
DE10336400A1 (en) * 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE10361596A1 (en) * 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
PT1842533E (en) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Dosage form that is secured against misuse
DE102005005446A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE102004020220A1 (en) * 2004-04-22 2005-11-10 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
WO2006079550A2 (en) 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
TWI365880B (en) * 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
ES2653568T3 (en) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Drug formulations for abuse prevention
CA2572491A1 (en) * 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse
DE102004032049A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
EP1786403B1 (en) * 2004-07-01 2013-07-24 Grünenthal GmbH Oral dosage form safeguarded against abuse containing (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
AU2005295482B2 (en) * 2004-10-15 2011-03-31 Supernus Pharmaceuticals Inc. Less abusable pharmaceutical preparations
FR2878161B1 (en) * 2004-11-23 2008-10-31 Flamel Technologies Sa ORAL MEDICINE FORM, SOLID AND DESIGNED TO AVOID MEASUREMENT
FR2878158B1 (en) * 2004-11-24 2009-01-16 Flamel Technologies Sa ORAL PHARMACEUTICAL FORM, SOLID MICROPARTICULAR DESIGNED TO PREVENT MEASUREMENT
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
FR2889810A1 (en) * 2005-05-24 2007-02-23 Flamel Technologies Sa ORAL MEDICINAL FORM, MICROPARTICULAR, ANTI-MEASUREMENT
FR2881652B1 (en) * 2005-02-08 2007-05-25 Flamel Technologies Sa MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
EP1917000A2 (en) * 2005-07-07 2008-05-07 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
CA2627351C (en) * 2005-10-26 2012-05-01 Banner Pharmacaps, Inc. Lipophilic vehicle-based dual controlled release matrix system
US8333989B2 (en) * 2005-10-26 2012-12-18 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
US20100210732A1 (en) * 2005-11-02 2010-08-19 Najib Babul Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor
WO2008134071A1 (en) * 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
FR2892937B1 (en) * 2005-11-10 2013-04-05 Flamel Tech Sa MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING
US8652529B2 (en) * 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
JP2009533443A (en) * 2006-04-10 2009-09-17 シャイア エルエルシー Mono- and disubstituted oxycodone compounds and compositions
WO2007120864A2 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
US7976872B2 (en) * 2006-07-24 2011-07-12 L. Perrigo Company Method for distributing a pharmaceutically active compound in an excipient
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8187636B2 (en) * 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
US8653106B2 (en) * 2010-07-30 2014-02-18 Pisgah Laboratories, Inc. Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
DE102007011485A1 (en) * 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
ES2692437T3 (en) 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Abuse-resistant drugs, method of use and method of preparation
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
ES2599031T3 (en) 2008-05-09 2017-01-31 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spray freezing step
BRPI0910780A2 (en) * 2008-07-07 2016-08-09 Euro Celtique Sa use of opioid antagonists for the treatment of urinary retention
AU2009289464B2 (en) * 2008-09-04 2015-12-10 Farnam Companies, Inc. Chewable sustained release formulations
AU2009311877C1 (en) * 2008-11-07 2013-08-15 Samyang Holdings Corporation Pharmaceutical composition for release control of methylphenidate
ES2414856T3 (en) * 2008-12-12 2013-07-23 Paladin Labs Inc. Narcotic drug formulations with decreased addiction potential
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
DK2405915T3 (en) 2009-03-10 2019-02-11 Euro Celtique Sa PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON
US20100307542A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Method of Reducing Surface Oil on Encapsulated Material
US9968564B2 (en) 2009-06-05 2018-05-15 Intercontinental Great Brands Llc Delivery of functional compounds
US20100310726A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
US8859003B2 (en) * 2009-06-05 2014-10-14 Intercontinental Great Brands Llc Preparation of an enteric release system
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
PT2456424E (en) * 2009-07-22 2013-09-30 Gruenenthal Gmbh Oxidation-stabilized tamper-resistant dosage form
NZ596667A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
JP5309262B2 (en) * 2009-12-02 2013-10-09 アプタリス ファーマ リミテッド Fexofenadine microcapsule and composition containing the same
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
EP2560624B1 (en) 2010-04-23 2018-07-04 KemPharm, Inc. Therapeutic formulation for reduced drug side effects
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
MX2013002377A (en) 2010-09-02 2013-04-29 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt.
CA2808541C (en) 2010-09-02 2019-01-08 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
CN103370058A (en) 2010-12-22 2013-10-23 普渡制药公司 Encased tamper resistant controlled release dosage forms
CN107412173A (en) 2010-12-23 2017-12-01 普渡制药公司 Anti-distort solid oral dosage form
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
AR087360A1 (en) 2011-07-29 2014-03-19 Gruenenthal Gmbh PROOF OF HANDLING TABLET PROVIDING IMMEDIATE RELEASE OF PHARMACY
MX348054B (en) 2011-07-29 2017-05-25 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release.
KR102180667B1 (en) * 2011-09-29 2020-11-20 피엘엑스 옵코 인코포레이티드 Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
EP2768481A4 (en) * 2011-10-21 2015-07-08 Subhash Desai Compositions for reduction of side effects
AU2013225106B2 (en) 2012-02-28 2017-11-02 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
RS57913B1 (en) 2012-04-18 2019-01-31 Gruenenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
MX2015010041A (en) 2013-02-05 2015-10-30 Purdue Pharma Lp Tamper resistant pharmaceutical formulations.
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
JP6466417B2 (en) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング A tamper-resistant dosage form with a bimodal release profile
JP6445537B2 (en) * 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper-resistant dosage forms containing one or more particles
JP6449871B2 (en) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Anti-modified dosage form containing ethylene-vinyl acetate polymer
KR20180037074A (en) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
BR112016010482B1 (en) 2013-11-26 2022-11-16 Grünenthal GmbH PREPARATION OF A PHARMACEUTICAL COMPOSITION IN POWDER BY MEANS OF CRYOMING
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
WO2015157138A1 (en) * 2014-04-07 2015-10-15 Banner Life Sciences Llc Abuse-deterrent controlled release formulations
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (en) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Multiparticulates protected against ethanol overdose
DK3157936T3 (en) 2014-06-18 2019-02-04 Thetis Pharmaceuticals Llc MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
EA035434B1 (en) 2015-04-24 2020-06-15 Грюненталь Гмбх Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
EP3210630A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
WO2020070547A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
CN112702995A (en) 2018-10-05 2021-04-23 克雷西奥生物科技有限公司 Treatment regimen of esketamine for treatment of major depression
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
CA3172595A1 (en) * 2020-03-26 2021-09-30 Ronald Zimmerman Pharmaceutical carriers capable of ph dependent reconstitution and methods for making and using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2404319A (en) * 1941-06-28 1946-07-16 Wm S Merrell Co Butanolamine salts of theophylline
US3015128A (en) * 1960-08-18 1962-01-02 Southwest Res Inst Encapsulating apparatus
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
DE2426812A1 (en) 1974-06-04 1976-01-02 Klinge Co Chem Pharm Fab PROCESS FOR THE MANUFACTURING OF GRANULES
DE2530563C2 (en) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgesic drugs with reduced potential for abuse
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
DK149776C (en) * 1984-01-06 1987-04-21 Orion Yhtymae Oy ANTIBIOTIC EFFECT OF ERYTHROMYCIN COMPOUND AND PREPARATION CONTAINING THE COMPOUND
KR920006865B1 (en) * 1984-05-18 1992-08-21 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 Method and apparatus for coating particles or liquid droplets
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
JPH0819004B2 (en) * 1986-12-26 1996-02-28 日清製粉株式会社 Sustained-release pharmaceutical preparation
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
TW225536B (en) * 1990-08-23 1994-06-21 Ciba Geigy Ag
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
SI9200139A (en) 1992-07-08 1994-03-31 Lek Tovarna Farmacevtskih New inclusion complex of clavulanic acid with hydrophylyc and hydropholyc beta-cyclodextrin derivates for production of them
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
PT689438E (en) * 1993-03-26 2003-10-31 Franciscus Wilhelmus He Merkus PHARMACEUTICAL COMPOSITIONS FOR INTROMASSAL ADMINISTRATION OF APOMORPHINE
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
EP1442745A1 (en) * 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
KR100354702B1 (en) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 Manufacturing method and sustained release composition of pharmaceutical composition
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
DE4413350A1 (en) * 1994-04-18 1995-10-19 Basf Ag Retard matrix pellets and process for their production
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
AUPN603895A0 (en) * 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
DE19607395C2 (en) 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salts from a cationic narcotic analgesic with an anionic non-narcotic analgesic, process for their preparation and the pharmaceutical preparations containing these salts
JP2000512649A (en) 1996-06-27 2000-09-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Sustained release sufentanil composition
CA2259418A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
WO1998010649A1 (en) * 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor
WO1998018827A1 (en) 1996-10-28 1998-05-07 Farmarc Nederland B.V. Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
AU9496798A (en) * 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
WO1999032119A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU742250B2 (en) * 1997-12-26 2001-12-20 Astellas Pharma Inc. Sustained release medicinal compositions
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
JP2003531099A (en) * 1999-03-24 2003-10-21 エフ エム シー コーポレーション Pharmaceutical formulations with improved water solubility
EP1204406A2 (en) 1999-07-29 2002-05-15 Roxane Laboratories, Inc. Opioid sustained-released formulation
DE19940740A1 (en) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmaceutical salts
HU229705B1 (en) * 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US20030113367A1 (en) 2000-03-28 2003-06-19 Penkler Lawrence John Alprazolam inclusion complexes and pharmaceutical compositions thereof
ATE376832T1 (en) 2001-07-06 2007-11-15 Penwest Pharmaceuticals Co DELAYED RELEASE FORMULATIONS OF OXYMORPHONE
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
JP2005506323A (en) * 2001-09-05 2005-03-03 ベクトゥラ・リミテッド Functional powder for oral delivery
US20030059397A1 (en) * 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
JP2005531495A (en) * 2001-12-21 2005-10-20 シャイア ラボラトリーズ，インコーポレイテッド Oral capsule formulation with high physical stability
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) * 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP4694207B2 (en) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド Abuse deterrent pharmaceutical compositions for opioids and other drugs
JP5189242B2 (en) * 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド Abuse-resistant pharmaceutical composition
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
EP2316418A3 (en) 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
ES2653568T3 (en) * 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Drug formulations for abuse prevention
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
WO2008027283A2 (en) * 2006-08-25 2008-03-06 Dow Global Technologies Inc. Production of meta-block copolymers by polymer segment interchange
US9737530B1 (en) * 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Also Published As

Publication number Publication date
WO2004004693A1 (en) 2004-01-15
EP1594467A1 (en) 2005-11-16
US9044398B2 (en) 2015-06-02
JP2006500426A (en) 2006-01-05
AU2003247876A1 (en) 2004-01-23
CA2491572C (en) 2010-03-23
US20130045960A1 (en) 2013-02-21
US20180028528A1 (en) 2018-02-01
US20150265596A1 (en) 2015-09-24
EP1594467A4 (en) 2008-10-22
AU2003247876B2 (en) 2006-10-05
JP4694207B2 (en) 2011-06-08
US20080260819A1 (en) 2008-10-23
JP2015166402A (en) 2015-09-24
JP2009298822A (en) 2009-12-24
US7399488B2 (en) 2008-07-15
US20080199530A1 (en) 2008-08-21
US20040052731A1 (en) 2004-03-18
JP2013216707A (en) 2013-10-24
JP2017101075A (en) 2017-06-08

Similar Documents

Publication Publication Date Title
CA2491572A1 (en) Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20200345722A1 (en) Abuse-deterrent drug formulations
US9248195B2 (en) Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10188644B2 (en) Process of making stable abuse-deterrent oral formulations
EP1414459B1 (en) Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2011066980A2 (en) Oral dosage forms with reduced potential for drug abuse
US10668060B2 (en) Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2955477A1 (en) Pharmaceutical abuse deterrent composition
US20210046014A1 (en) Pharmaceutical abuse deterrent composition constructed in more than one strengths
WO2019064082A2 (en) Pharmaceutical abuse deterrent composition constructed in more than one strengths

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831